The Utility of PSADv (PSA Density Velocity) While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage

Status unconfirmed

Conditions studied: Prostate Cancer

In brief

This is a review of previously published data from a large prostate cancer prevention study known as REDUCE. It is the investigators intention to review whether prostate specific antigen (PSA) velocity (change over time) will predict the presence of prostate cancer and its grade and stage (severity).

Key facts

Study ID

NCT01484808

Run by

University Urological Associates Inc.

People needed

6600

Starts

2012-01-01

Expected to finish

2012-05-01

Last updated by the study team

2011-12-02

Who can join

Age: 50 and older, up to 74. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men,
• 50-74 years old with elevated PSA (>=4) along with negative entry biopsy of the prostate who had a subsequent biopsy by 24 months.

You may not qualify if…

• Any positive biopsy of the prostate indicative of cancer upon entry

Where it is running

• Division of Urology, Brown University — Providence, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.